BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
Number Cited Articles
1
M. Tabib, H. Zolgharnein, M. Mohammadi, M.A. Salari-Aliabadi, A. Qasemi, S. Roshani, H. Rajabi-Maham, F. Frootan. mtDNA variation of the critically endangered hawksbill turtle (Eretmochelys imbricata) nesting on Iranian islands of the Persian GulfGenetics and Molecular Research 2011; 10(3): 1499 doi: 10.4238/vol10-3gmr1148
2
Doença do refluxo gastroesofágico: tratamento farmacológicoRevista da Associação Médica Brasileira 2011; 57(6): 617 doi: 10.1590/S0104-42302011000600006
3
Kwong Ming Fock, Tiing Leong Ang, Lean Choo Bee, Edmund Jon Deon Lee. Proton Pump InhibitorsClinical Pharmacokinetics 2008; 47(1): 1 doi: 10.2165/00003088-200847010-00001
4
Stefano Pallotta, Fabio Pace, Silvia Marelli. Rabeprazole: a second-generation proton pump inhibitor in the treatment of acid-related diseaseExpert Review of Gastroenterology & Hepatology 2008; 2(4): 509 doi: 10.1586/17474124.2.4.509
5
A. EGGLESTON, P. H. KATELARIS, S. NANDURKAR, P. THORPE, G. HOLTMANN. Clinical trial: the treatment of gastro-oesophageal reflux disease in primary care - prospective randomized comparison of rabeprazole 20 mg with esomeprazole 20 and 40 mgAlimentary Pharmacology & Therapeutics 2009; 29(9): 967 doi: 10.1111/j.1365-2036.2009.03948.x
6
Victoria P. Y. Tan, Wai M. Wong, Ting K. Cheung, Kam C. Lai, Ivan F. N. Hung, Pierre Chan, Roberta Pang, Benjamin C. Y. Wong. Treatment of non-erosive reflux disease with a proton pump inhibitor in Chinese patients: a randomized controlled trialJournal of Gastroenterology 2011; 46(7): 906 doi: 10.1007/s00535-011-0402-1
7
Shaojun Shi, Ulrich Klotz. Proton pump inhibitors: an update of their clinical use and pharmacokineticsEuropean Journal of Clinical Pharmacology 2008; 64(10): 935 doi: 10.1007/s00228-008-0538-y
8
Alia Dadabhai, Frank K Friedenberg. Rabeprazole: a pharmacologic and clinical review for acid-related disordersExpert Opinion on Drug Safety 2009; 8(1): 119 doi: 10.1517/14740330802622892
9
Kiyoshi Ashida, Yoshikazu Kinoshita, Michio Hongo. Acid-Suppressive Effect of Rabeprazole 5 mg and 10 mg Once Daily by 24-Hour Esophageal pH Monitoring in Patients with Non-erosive Reflux Disease in Japan: A Multicenter, Randomized, Parallel-Group, Double-Blind Pharmacodynamic StudyDigestive Diseases and Sciences 2011; 56(8): 2333 doi: 10.1007/s10620-011-1583-4
10
S. Sahara, M. Sugimoto, T. Uotani, H. Ichikawa, M. Yamade, M. Iwaizumi, T. Yamada, S. Osawa, K. Sugimoto, K. Umemura, H. Miyajima, T. Furuta. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazoleAlimentary Pharmacology & Therapeutics 2013; 38(9): 1129 doi: 10.1111/apt.12492
11
Hao Li, Ling Meng, Fei Liu, Ji-Fu Wei, Yong-Qing Wang. H+/K+-ATPase inhibitors: a patent reviewExpert Opinion on Therapeutic Patents 2013; 23(1): 99 doi: 10.1517/13543776.2013.741121
12
Akihito Nagahara, Hiroto Miwa, Daisuke Asaoka, Yuji Shimada, Hitoshi Sasaki, Kenshi Matsumoto, Taro Osada, Mariko Hojo, Sumio Watanabe. Pretreatment prediction of symptom response to proton pump inhibitor therapyJournal of Gastroenterology and Hepatology 2015; 30: 25 doi: 10.1111/jgh.12744
13
Consuelo L Saccar. The pharmacology of esomeprazole and its role in gastric acid related diseasesExpert Opinion on Drug Metabolism & Toxicology 2009; 5(9): 1113 doi: 10.1517/17425250903124363
14
H. MIWA, M. SASAKI, T. FURUTA, T. KOIKE, Y. HABU, M. ITO, Y. FUJIWARA, T. WADA, A. NAGAHARA, M. HONGO, T. CHIBA, Y. KINOSHITA. Efficacy of rabeprazole on heartburn symptom resolution in patients with non-erosive and erosive gastro-oesophageal reflux disease: a multicenter study from JapanAlimentary Pharmacology & Therapeutics 2007; 26(1): 69 doi: 10.1111/j.1365-2036.2007.03350.x
15
Alan B. R. Thomson. Standard doses of the oral proton pump inhibitors are clinically equivalent: A comparisonCurrent GERD Reports 2007; 1(4): 223 doi: 10.1007/s12171-007-0022-0
16
P. W. Weijenborg, F. Cremonini, A. J. P. M. Smout, A. J. Bredenoord. PPI therapy is equally effective in well-defined non-erosive reflux disease and in reflux esophagitis: a meta-analysisNeurogastroenterology & Motility 2012; 24(8): 747 doi: 10.1111/j.1365-2982.2012.01888.x
17
M. MIKI, K. ADACHI, T. AZUMI, K. KOSHINO, K. FURUTA, Y. KINOSHITA. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way crossover studyAlimentary Pharmacology and Therapeutics 2006; 24(10): 1445 doi: 10.1111/j.1365-2036.2006.03140.x
18
K. R. DEVAULT. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburnAlimentary Pharmacology and Therapeutics 2006; 23(s1): 33 doi: 10.1111/j.1365-2036.2006.02798.x
19
Claudine M. Baldwin, Susan J. Keam. RabeprazoleDrugs 2009; 69(10): 1373 doi: 10.2165/00003495-200969100-00007
20
Gastroesophageal reflux disease: drug therapyRevista da Associação Médica Brasileira (English Edition) 2011; 57(6): 603 doi: 10.1016/S2255-4823(11)70124-2
21
Akihito Nagahara, Tsuyoshi Suzuki, Naoyoshi Nagata, Nozomu Sugai, Yoshiaki Takeuchi, Kouichi Sakurai, Masaki Miyamoto, Kazuhiko Inoue, Junichi Akiyama, Katsuhiro Mabe, Ichiro Konuma, Tomoari Kamada, Ken Haruma. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitisJournal of Gastroenterology 2014; 49(12): 1536 doi: 10.1007/s00535-013-0925-8
22
Motoyasu Kusano, Naohito Shirai, Kanako Yamaguchi, Michio Hongo, Tsutomu Chiba, Yoshikazu Kinoshita. It Is Possible to Classify Non-erosive Reflux Disease (NERD) Patients into Endoscopically Normal Groups and Minimal Change Groups by Subjective Symptoms and Responsiveness to Rabeprazole—A Report from a Study with Japanese PatientsDigestive Diseases and Sciences 2008; 53(12): 3082 doi: 10.1007/s10620-008-0290-2
23
Takuma Kagami, Mitsushige Sugimoto, Hitomi Ichikawa, Shu Sahara, Takahiro Uotani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Ken Sugimoto, Hiroaki Miyajima, Takahisa Furuta. One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19European Journal of Clinical Pharmacology 2015; 71(12): 1467 doi: 10.1007/s00228-015-1941-9
24
Joaquim Prado P. Moraes-Filho, Tomas Navarro-Rodriguez, Ricardo Barbuti, Jaime Eisig, Decio Chinzon, Wanderley Bernardo. Guidelines for the diagnosis and management of gastroesophageal reflux disease: an evidence-based consensusArquivos de Gastroenterologia 2010; 47(1): 99 doi: 10.1590/S0004-28032010000100017
25
Kwong Ming Fock, Nicholas J Talley, Ronnie Fass, Khean Lee Goh, Peter Katelaris, Richard Hunt, Michio Hongo, Tiing Leong Ang, Gerald Holtmann, Sanjay Nandurkar, San Ren Lin, Benjamin CY Wong, Francis KL Chan, Abdul Aziz Rani, Young-Tae Bak, Jose Sollano, Lawrence KY Ho, Sathoporn Manatsathit. Asia-Pacific consensus on the management of gastroesophageal reflux disease: UpdateJournal of Gastroenterology and Hepatology 2007; 23(1): 8 doi: 10.1111/j.1440-1746.2007.05249.x
26
E. S. LEE, N. KIM, S. H. LEE, Y. S. PARK, J. W. KIM, S. H. JEONG, D. H. LEE, H. C. JUNG, I. S. SONG. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux diseaseAlimentary Pharmacology & Therapeutics 2009; 30(2): 154 doi: 10.1111/j.1365-2036.2009.04021.x
27
Y. Kinoshita, K. Ashida, M. Hongo. Randomised clinical trial: a multicentre, double-blind, placebo-controlled study on the efficacy and safety of rabeprazole 5 mg or 10 mg once daily in patients with non-erosive reflux diseaseAlimentary Pharmacology & Therapeutics 2011; 33(2): 213 doi: 10.1111/j.1365-2036.2010.04508.x
28
B. Al-Judaibi, N. Chande, G.K. Dresser, N. Sultan, J.C. Gregor. Gastric Acid-Related Diseases: Focus on EsomeprazoleClinical Medicine Insights: Therapeutics 2010; 2: CMT.S4500 doi: 10.4137/CMT.S4500
29
Jing Sun, Yao-Zong Yuan, Xiao-Hua Hou, Duo-Wu Zou, Bin Lu, Min-Hu Chen, Fei Liu, Kai-Chun Wu, Xiao-Ping Zou, Yan-Qing Li, Li-Ya Zhou. Esomeprazole regimens for reflux symptoms in Chinese patients with chronic gastritisWorld Journal of Gastroenterology 2015; 21(22): 6965-6973 doi: 10.3748/wjg.v21.i22.6965
30
J. HORN. Review article: understanding the pharmacodynamic and pharmacokinetic differences between proton pump inhibitors - focus on pKa and metabolismAlimentary Pharmacology <html_ent glyph="@amp;" ascii="&amp;"/> Therapeutics Symposium Series 2006; 2(2): 340 doi: 10.1111/j.1746-6342.2006.00065.x
31
Sanjay Nandurkar. Frequency scale symptoms for gastroesophageal reflux disease (Frequency Scale for Symptoms of GERD) predicts need for addition of prokinetics to proton pump inhibitor therapyJournal of Gastroenterology and Hepatology 2008; 23(8pt1): 1165 doi: 10.1111/j.1440-1746.2008.05517.x
32
Ravi Vachhani, Gregory Olds, Vic Velanovich. Esomeprazole: a proton pump inhibitorExpert Review of Gastroenterology & Hepatology 2009; 3(1): 15 doi: 10.1586/17474124.3.1.15
33
Gastroesophageal reflux disease: drug therapyRevista da Associação Médica Brasileira 2011; 57(6): 603 doi: 10.1016/S0104-4230(11)70124-5
34
M R Craven, L Kia, L C O’Dwyer, E Stern, T H Taft, L Keefer. Systematic review: methodological flaws in racial/ethnic reporting for gastroesophageal reflux disease Diseases of the Esophagus 2018; 31(3) doi: 10.1093/dote/dox154
35
Toru Hiyama, Keitaro Matsuo, Yuji Urabe, Tatsuma Fukuhara, Shinji Tanaka, Masaharu Yoshihara, Ken Haruma, Kazuaki Chayama. Meta-analysis used to identify factors associated with the effectiveness of proton pump inhibitors against non-erosive reflux diseaseJournal of Gastroenterology and Hepatology 2009; 24(8): 1326 doi: 10.1111/j.1440-1746.2009.05879.x
36
Motoyasu Kusano, Shikou Kuribayashi, Osamu Kawamura, Yasuyuki Shimoyama, Hiroko Hosaka, Atsuto Nagoshi, Hiroaki Zai, Masatomo Mori. A Review of the Management of Gastric Acid-Related Diseases: Focus on RabeprazoleClinical Medicine. Gastroenterology 2011; 4: CGast.S5133 doi: 10.4137/CGast.S5133